Preclinical target validation using patient-derived cells Aled M. Edwards , Cheryl H. Arrowsmith , Chas Bountra , Mark E. Bunnage , Marc Feldmann , Julian C. Knight , Dhavalkumar D. Patel , Panagiotis Prinos , Michael D. Taylor , Michael Sundström , Phil Barker , Dalia Barsyte , Mario H. Bengtson , Cindy Bell , Paul Bowness , Kym M. Boycott , Carolyn Buser-Doepner , Christopher L. Carpenter , Andrew J. Carr , Kirk Clark , Anuk M. Das , Dashyant Dhanak , Peter Dirks , James Ellis , Valeria R. Fantin , Christopher Flores , Edward A. Fon , Donald E. Frail , Opher Gileadi , Ronan C. O'Hagan , Trevor Howe , John T. R. Isaac , Nada Jabado , Per-Johan Jakobsson , Lars Klareskog , Stefan Knapp , Wen Hwa Lee , Evelyne Lima-Fernandes , Ingrid E. Lundberg , John Marshall , Katlin B. Massirer , Alex E. MacKenzie , Tetsuyuki Maruyama , Anke Mueller-Fahrnow , Senthil Muthuswamy , Jagdeep Nanchahal , Catherine O'Brien , Udo Oppermann , Nils Ostermann , Kevin Petrecca , Bruce G. Pollock , Viviane Poupon , Rab K. Prinjha , Saul H. Rosenberg , Guy Rouleau , Malcolm Skingle , Arthur S. Slutsky , Garth A. M. Smith , Dominique Verhelle , Hans Widmer , L. Trevor Young NATURE REVIEWS DRUG DISCOVERY（2015）
摘要
The Structural Genomics Consortium (SGC) and its clinical, industry and disease-foundation partners are launching open-source preclinical translational medicine studies.
更多 查看译文
关键词
Small molecules, Phenotypic screening, Drug discovery and development, Drug development, Stem-cell biotechnology
AI 理解论文
溯源树
样例
